Venetoclax ex vivo functional profiling predicts improved progression-free survival
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2044-5385
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Venetoclax ex vivo functional profiling predicts improved progression-free survival ; volume:12 ; number:8 ; day:4 ; month:8 ; year:2022 ; pages:1-4 ; date:8.2022
Blood cancer journal ; 12, Heft 8 (4.8.2022), 1-4, 8.2022
- Urheber
-
Gupta, Vikas A.
Matulis, Shannon M.
Barwick, Benjamin G.
Bog, R. Devin
Shebelut, Conrad W.
Shanmugam, Mala
Neri, Paola
Bahlis, Nizar J.
Dhodapkar, Madhav V.
Heffner, Leonard T.
Hofmeister, Craig C.
Joseph, Nisha S.
Lonial, Sagar
Kaufman, Jonathan L.
Jaye, David L.
Nooka, Ajay K.
Boise, Lawrence H.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41408-022-00710-9
- URN
-
urn:nbn:de:101:1-2022101920535748855955
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gupta, Vikas A.
- Matulis, Shannon M.
- Barwick, Benjamin G.
- Bog, R. Devin
- Shebelut, Conrad W.
- Shanmugam, Mala
- Neri, Paola
- Bahlis, Nizar J.
- Dhodapkar, Madhav V.
- Heffner, Leonard T.
- Hofmeister, Craig C.
- Joseph, Nisha S.
- Lonial, Sagar
- Kaufman, Jonathan L.
- Jaye, David L.
- Nooka, Ajay K.
- Boise, Lawrence H.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients
[18F]FDG PET/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis
Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma
Androgen receptor profiling predicts prostate cancer outcome
Venetoclax – The Game-changer in Hematology
Microfluidic-based dynamic BH3 profiling predicts anticancer treatment efficacy
Progression-free sets and rank of matrices
Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy
CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)
Venetoclax - ein neuer Therapiestandard in der AML
Venetoclax bei der chronischen lymphatischen Leukämie (CLL)
Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma
Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients
[18F]FDG PET/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis
Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma
Androgen receptor profiling predicts prostate cancer outcome
Venetoclax – The Game-changer in Hematology
Microfluidic-based dynamic BH3 profiling predicts anticancer treatment efficacy
Progression-free sets and rank of matrices
Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy
CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)
Venetoclax - ein neuer Therapiestandard in der AML
Venetoclax bei der chronischen lymphatischen Leukämie (CLL)
Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma
Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients
[18F]FDG PET/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis
Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma
Androgen receptor profiling predicts prostate cancer outcome
Venetoclax – The Game-changer in Hematology
Microfluidic-based dynamic BH3 profiling predicts anticancer treatment efficacy
Progression-free sets and rank of matrices
Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy
CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)
Venetoclax - ein neuer Therapiestandard in der AML
Venetoclax bei der chronischen lymphatischen Leukämie (CLL)